Useful Combination of Antibodies for Immunophenotyping ALL
| Purpose . | Label-CD Cluster . |
|---|---|
| By plotting side scatter (SSC)v CD45, malignant T and B cells can often be resolved from normal cells by their degree of CD45 expression. B cells are often HLADR+, but not T cells. CD20 expression can aid in determining the maturity of B-cell malignancy while CD5 expression in the absence of CD20 expression is associated with T-cells. | FITC-CD20 PE-CD5 PP-HLADR APC-CD45 |
| Designed to evaluate myeloid CD13+ coexpression on B-lineage (CD22) v T-lineage CD2+/CD7+ malignancy. T-lineage malignancy often exhibits over or underexpression of CD2 and/or CD7. | FITC-CD7 PE-CD22 PP-CD2 APC-CD13 |
| Designed to evaluate CD19+ subgroups of B-lineage ALL with respect to CD10, CD38, and CD34 expression. | FITC-CD38 PE-CD19 PP-CD10 APC-CD34 |
| This combination is designed to evaluate subgroups of T-lineage ALL with respect to CD1/CD4/CD8 and CD3 expression. Overexpression or underexpression of one or more of these markers is often found in T-lineage malignancy. | FITC-CD1 PE-CD4 PP-CD8 APC-CD3 |
| Purpose . | Label-CD Cluster . |
|---|---|
| By plotting side scatter (SSC)v CD45, malignant T and B cells can often be resolved from normal cells by their degree of CD45 expression. B cells are often HLADR+, but not T cells. CD20 expression can aid in determining the maturity of B-cell malignancy while CD5 expression in the absence of CD20 expression is associated with T-cells. | FITC-CD20 PE-CD5 PP-HLADR APC-CD45 |
| Designed to evaluate myeloid CD13+ coexpression on B-lineage (CD22) v T-lineage CD2+/CD7+ malignancy. T-lineage malignancy often exhibits over or underexpression of CD2 and/or CD7. | FITC-CD7 PE-CD22 PP-CD2 APC-CD13 |
| Designed to evaluate CD19+ subgroups of B-lineage ALL with respect to CD10, CD38, and CD34 expression. | FITC-CD38 PE-CD19 PP-CD10 APC-CD34 |
| This combination is designed to evaluate subgroups of T-lineage ALL with respect to CD1/CD4/CD8 and CD3 expression. Overexpression or underexpression of one or more of these markers is often found in T-lineage malignancy. | FITC-CD1 PE-CD4 PP-CD8 APC-CD3 |